Evidence map›Paper›PMID 41897416›Full record

ArticleBiomolecules2026

Targeting LIPA with ERX-41 Induces ER Stress and Inhibits Tumor Progression in Inflammatory Breast Cancer.

Zenaida Fuentes, Gaurav Sharma, Bianca A Romo, Rahul Gopalam, Khaled Mohamed Nassar, Paulina Ramirez, Nicole Mejia, Chia-Yuan Chen, Scott Elmore, Henry Neal and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Zenaida FuentesDepartment of Obstetrics and Gynecology, University of Texas Health San Antonio, San Antonio, TX 78229, USA.ORCID 0009-0009-7676-4449
Gaurav SharmaDepartment of Obstetrics and Gynecology, University of Texas Health San Antonio, San Antonio, TX 78229, USA.ORCID 0000-0001-7377-0880
Bianca A RomoDepartment of Biology, University of the Incarnate Word, San Antonio, TX 78209, USA.
Rahul GopalamDepartment of Obstetrics and Gynecology, University of Texas Health San Antonio, San Antonio, TX 78229, USA.
Khaled Mohamed NassarDepartment of Obstetrics and Gynecology, University of Texas Health San Antonio, San Antonio, TX 78229, USA.
Paulina RamirezDepartment of Obstetrics and Gynecology, University of Texas Health San Antonio, San Antonio, TX 78229, USA.
Nicole MejiaDepartment of Obstetrics and Gynecology, University of Texas Health San Antonio, San Antonio, TX 78229, USA.ORCID 0009-0001-4519-3892
Chia-Yuan ChenDepartment of Chemistry and Biochemistry, University of Texas at Dallas, Richardson, TX 75080, USA.
Scott ElmoreDepartment of Chemistry and Biochemistry, University of Texas at Dallas, Richardson, TX 75080, USA.
Henry NealDepartment of Chemistry and Biochemistry, University of Texas at Dallas, Richardson, TX 75080, USA.
Harika NagandlaHouston Methodist Neal Cancer Center, Houston Methodist Research Institute, Houston, TX 77030, USA.
Panneerdoss SubbarayaluGreehey Children's Cancer Research Institute, University of Texas Health San Antonio, San Antonio, TX 78229, USA.
Uday P PratapDepartment of Obstetrics and Gynecology, University of Texas Health San Antonio, San Antonio, TX 78229, USA.
Christoforos ThomasHouston Methodist Neal Cancer Center, Houston Methodist Research Institute, Houston, TX 77030, USA.ORCID 0000-0003-3003-2954
Jung-Mo AhnDepartment of Chemistry and Biochemistry, University of Texas at Dallas, Richardson, TX 75080, USA.ORCID 0000-0002-9104-525X
Ganesh V RajEtiraRx Inc., Dallas, TX 75247, USA.
Suryavathi ViswanadhapalliDepartment of Obstetrics and Gynecology, University of Texas Health San Antonio, San Antonio, TX 78229, USA.ORCID 0000-0002-7381-6962
Ratna K VadlamudiDepartment of Obstetrics and Gynecology, University of Texas Health San Antonio, San Antonio, TX 78229, USA.ORCID 0000-0003-2849-4076

Funding

Epigenetics, DNA repair and Genomics (EDGe) Training Program in CancerT32CA279363 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Robin Jean Leach, Anna L Malkova · 2024 to 2026
$493k
NCI NIH HHS CA262757NCI NIH HHS CA267893NCI NIH HHS T32 CA279363United States Department of Defense W81XWH-22-1-0180VA 101 BX004545
6 · The paper itself

Abstract

Approximately 2-4% of all breast cancer cases are inflammatory breast cancer (IBC), an extremely rare and severe subtype of the disease. Current therapies, including chemotherapy, surgery, and radiotherapy, remain insufficient, underscoring the need for novel therapeutic approaches. IBC exhibits elevated basal endoplasmic reticulum (ER) stress, suggesting a potential vulnerability. We recently developed ERX-41, a small molecule that exacerbates ER stress in cancer cells by inhibiting the endoplasmic reticulum-localized function of Lysosomal acid lipase A (LIPA). Here, we evaluated the therapeutic potential of ERX-41 in IBC models. ERX-41 markedly reduced the viability of IBC cells and significantly impaired clonogenic survival while promoting apoptosis. The specificity of ERX-41 was confirmed using LIPA-knockdown and LIPA-knockout cells. RT-PCR-based assays revealed rapid induction of

Indexed as

Antineoplastic AgentsEndoplasmic Reticulum StressInflammatory Breast NeoplasmsAnimalsApoptosisCell Line, TumorCell ProliferationCell SurvivalDisease ProgressionFemaleHumansMiceXenograft Model Antitumor AssaysAntineoplastic Agentsbreast cancerER stressERX-41inflammatory breast cancerLIPA

Identifiers

PMID41897416
PMCPMC13023744

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.